HIV-Related Stigma Intervention for Malaysian Clinicians

Sponsor
University of Delaware (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05597787
Collaborator
University of Malaya (Other)
78
1
3
9.2
8.5

Study Details

Study Description

Brief Summary

Key populations at risk of HIV (including men who have sex with men, people who inject drugs, transgender women, and female sex workers) are more likely to be infected with HIV but less likely than members of the general population to know of their HIV status, receive HIV prevention counseling, or be linked to HIV care services. Clinician stigma towards these groups remains a potent and persistent driver of these HIV disparities in many places of the world. The investigators propose to incorporate evidence-based stigma reduction tools into a popular teletraining platform for clinicians and pilot test the resulting intervention (Project ECHO® for HIV Prevention and Stigma Reduction) with clinicians in Malaysia, a context wherein clinician stigma and HIV disparities are substantial.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Stigma Reduction Tools
  • Behavioral: Education
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
78 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Care Provider)
Primary Purpose:
Screening
Official Title:
Implementing Stigma Reduction Tools Via a Popular Teletraining Platform to Reduce Clinician Stigma and Disparities in HIV Testing, Prevention, and Linkage to Care in Malaysia
Actual Study Start Date :
Jul 26, 2022
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
May 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: HIV Connect

Participants randomized to this condition will complete HIV Connect, which is an online course developed by the Malaysian Society of HIV Medicine designed to educate primary care physicians in Malaysia about HIV. It consists of a series of modules featuring HIV infectious disease experts who instruct on topics including epidemiology and natural history of HIV, pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), sexual history taking and STI testing, and others.

Behavioral: Education
education and clinical skills

Active Comparator: Project ECHO for HIV Prevention

Participants randomized to this condition will receive Project ECHO for HIV Prevention, without added evidence-based stigma reduction tools. Participants will meet with the Project ECHO Hub specialists and their learning community on a bi-weekly basis for 60 minutes over the course of 9 months. Each session will feature a didactic training incorporating standardized procedures for HIV testing, prevention, and/or linkage to care, and patient-case presentation and discussion.

Behavioral: Education
education and clinical skills

Experimental: Project ECHO for HIV Prevention + Stigma Reduction

Participants randomized to this condition will receive the Project ECHO for HIV Prevention intervention with added evidence-based stigma reduction tools. Participants will meet with the Project ECHO Hub specialists and their learning community on a bi-weekly basis for 60 minutes over the course of 9 months. Each session will feature a didactic training incorporating standardized procedures for HIV testing, prevention, and/or linkage to care, and patient-case presentation and discussion.

Behavioral: Stigma Reduction Tools
behavioral design, contact, and social norms

Behavioral: Education
education and clinical skills

Outcome Measures

Primary Outcome Measures

  1. Acceptability of Intervention [Month 9 Assessment]

    Measured with Acceptability of Intervention Measure (adapted from Weiner et al., 2017). Items are measured on 5-point, Likert-type scale and will be averaged for analysis.

  2. Feasibility of Intervention [Month 9 Assessment]

    Measured with Feasibility of Intervention Measure (adapted from Weiner et al., 2017). Items are measured on 5-point, Likert-type scale and will be averaged for analysis.

  3. Stigma Reduction: Prejudice [Month 9 Assessment]

    Measured with Feelings Thermometers (adapted from Alwin, 1997). Positive/Negative affect is measured on 0-100 point scale.

  4. Stigma Reduction: Stereotypes [Month 9 Assessment]

    Measured with subscale of Multidimensional HIV-Related Stigma Scale (adapted from Stein & Li, 2007). Items are measured on 5-point, Likert-type scale and will be averaged for analysis.

  5. Stigma Reduction: Discrimination [Month 9 Assessment]

    Measured with subscale of Multidimensional HIV-Related Stigma Scale (adapted from Stein & Li, 2007). Items are measured on 5-point, Likert-type scale and will be averaged for analysis.

Secondary Outcome Measures

  1. HIV Prevention Procedures: HIV Testing [Cumulative over 9 month intervention]

    Measured with weekly diary of HIV tests performed. Number of HIV tests will be summed over duration of intervention.

  2. HIV Prevention Procedures: PrEP Prescriptions [Cumulative over 9 month intervention]

    Measured with weekly diary of PrEP prescriptions. Number of PrEP prescriptions will be summed over duration of intervention.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • practicing general practitioner or family medicine specialist in Malaysia
Exclusion Criteria:

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Malaya Kuala Lumpur Malaysia

Sponsors and Collaborators

  • University of Delaware
  • University of Malaya

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Delaware
ClinicalTrials.gov Identifier:
NCT05597787
Other Study ID Numbers:
  • R34MH124390
First Posted:
Oct 28, 2022
Last Update Posted:
Oct 28, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Oct 28, 2022